42 results
Page 2 of 3
8-K
EX-99.1
eri2najm
11 Jan 21
Regulation FD Disclosure
8:31am
8-K
EX-99.1
16mvx8prbwh42jpi8n
10 Aug 20
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
7:20am
S-3
EX-1.1
4yln10mr26cyhv6
20 Dec 19
Shelf registration
4:17pm
8-K
EX-99.2
8zk0 t3v4d3
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
10-Q
dvsf1dms z0k
9 May 19
Quarterly report
7:13am
10-K
7o7bp6k
28 Feb 19
Annual report
1:08pm
424B5
4kh4j5t omcjih
25 Jan 19
Prospectus supplement for primary offering
8:01am
8-K
EX-1.1
p6n81s0omzaew92qq
25 Jan 19
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
7:30am
424B5
hr7hq6r ixj8z09
22 Jan 19
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.2
5gqw3dg
22 Jan 19
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
5:08pm
F-3
EX-1.2
ju7agt
12 Oct 18
Shelf registration (foreign)
5:24pm